Citi on Harmony (HRMY): 'FDA Denies Short Seller Citizens’ Petition to Remove Wakix from the Market, Ending Unwarranted Safety Claims'
Tweet Send to a Friend
Citi analyst David Hoang reiterated a Buy rating and $48.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
